IN8bio Q1 net loss narrows as R&D expenses fall

IN8bio

07/05/2026 21:43

Overview

US biopharma firm's Q1 net loss narrowed from prior year as R&D expenses declined

Company's cash position rose to $21.9 mln from $11.9 mln a year earlier

Outlook

Company expects initial animal data for INB-619 T cell engager platform in 2026

IN8bio anticipates FDA guidance on regulatory pathways for GBM program in 2H26

Result Drivers

LOWER R&D SPENDING - Co said decrease in R&D expenses was mainly due to reduced clinical trial activity in the INB-400 program

Company press release: ID:nGNX3z8qMs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$5.09 mln
Q1 Basic EPS
-$0.26
Q1 Operating Expenses
$5.27 mln
Q1 Operating Income
-$5.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for IN8bio Inc is $5.00, about 216.5% above its May 6 closing price of $1.58

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)